News

Brandeis University

Form I-765 Brandeis Supplemental Instructions

If you file your OPT/STEM OPT application by mail, you must complete a paper Form I-765, Application for Employment Authorization, and follow the U.S. Citizenship and Immigration Services (USCIS) ...
FierceBiotech

Press Release: Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer

Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer Nexavar is First Drug Therapy to Demonstrate Significant Survival Benefit in Liver Cancer WAYNE, N.J. and ...
Business Wire

Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma | Business Wire

Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma – U.S. Food and Drug Administration assigns ...
FierceBiotech

Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZ® (tofacitinib citrate) Labeling to Include Additional Patient-Reported Outcomes Data for Adults ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate) to include ...

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of ...

INDICATION LEQEMBI ® is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of ...